Long-term-Vitrakvi-larotrectinib-confirm-sustained-clinical-benefit-greater-years-patients-TRK

Larotrectinib achieved 75% (95% CI 68-81) overall response rate (ORR) and median duration of response (DoR) of 49.3 months (95% CI 27.3-not estimable [NE]) in expanded integrated dataset of 206 evaluable adults and children with TRK fusion cancer, which occurs when an NTRK gene fuses with another unrelated gene, across 21 different tumor types and regardless of age (range: 0.1-84 years) with longer follow-up at a median follow-up of 22.3 months / In tumor-specific analyses, larotrectinib demonstrated rapid and durable responses, and long disease control, among patients with lung and primary central nervous system (CNS) TRK fusion cancers / Intra-patient comparison showed majority of TRK fusion cancer patients experienced a meaningful clinical benefit with larotrectinib compared to their prior line of therapy Majority of adverse events (AEs) were Grade 1 or 2 and no new safety signals were identified
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news